Who founded Nested Therapeutics?

Nested Therapeutics was founded by Arvin Dar, Kevan Shokat, Klaus Hoeflich in 2021.

Who are Nested Therapeutics's investors?

Nested Therapeutics's investors include Versant Ventures, Foresite Capital, Sixty Degree Capital, Cowen Healthcare Investments, Goldman Sachs, Section 32.

Nested Therapeutics

Founded 2021 · 16 employees on LinkedIn · 6 known investors

Find your way into Nested Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Nested Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.

AI & Machine Learning Biotech Healthtech

Founders & leadership

Nested Therapeutics was founded in 2021 by Arvin Dar, Kevan Shokat, and Klaus Hoeflich.

Arvin DarCo-founder & Board Observer

Kevan ShokatScientific Co-founder

Klaus HoeflichCo-founder & former Chief Scientific OfficerCo-founder and former Chief Scientific Officer of Nested Therapeutics, a precision oncology company. Hoeflich has advanced cancer drug candidates through target discovery, IND submission, and clinical development, with experience in R&D leadership and establishing academic and industry partnerships.

Darrin MilesChief Executive Officer

Philip KomarnitskyChief Medical OfficerPhilip Komarnitsky is Chief Medical Officer at Nested Therapeutics, a precision oncology company developing small-molecule cancer therapeutics. His background includes expertise in clinical and pre-clinical drug development, as well as product licensing due diligence.

Tanja WeberChief Business Officer

Investors · 6

Versant Ventures✓ confirmed by Nested TherapeuticsSan Francisco · $250K – $5M

How we know: Versant Ventures's portfolio page · the company's own site · a partner's Signal profile · Not right? Tell us

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · press coverage · Not right? Tell us

Sixty Degree Capitallisted by Sixty Degree CapitalNorth York

How we know: Sixty Degree Capital's portfolio page · Not right? Tell us

Cowen Healthcare InvestmentsreportedNew York

How we know: funding news · press coverage · Not right? Tell us

Goldman SachsreportedNew York

How we know: funding news · press coverage · Not right? Tell us

Section 32reportedPalo Alto

How we know: press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountseries AOct 2022
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Frequently asked questions

What does Nested Therapeutics do?: Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.
Who founded Nested Therapeutics?: Nested Therapeutics was founded by Arvin Dar, Kevan Shokat, Klaus Hoeflich in 2021.
Who are Nested Therapeutics's investors?: Nested Therapeutics's investors include Versant Ventures, Foresite Capital, Sixty Degree Capital, Cowen Healthcare Investments, Goldman Sachs, Section 32.